>

Evusheld

  • Vanderbilt University

    Supercomputing redesign of a COVID monoclonal antibody

    One of the monoclonal antibodies in the therapeutic Evusheld has been computationally redesigned to restore its action against Omicron variants of the virus that causes COVID-19. Read More

    May. 14, 2024

  • Vanderbilt University

    James Crowe awarded “TIME” Best Inventions of 2022

    Dr. James Crowe Jr., director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center, led the team that discovered a monoclonal antibody combination that protects against COVID-19. Optimized and developed by AstraZeneca, the monoclonal antibody combination called  Evusheld is the first treatment… Read More

    Dec. 5, 2022

  • Dr. James Crowe Jr., professor of medicine, in his lab at Medical Research Building IV. Dr. Crowe is the subject of a feature article in the upcoming Winter 2018 issue of Vanderbilt Magazine. Crowe, who is the Ann Scott Carell Professor of Pediatrics, Pathology, Microbiology and Immunology, as well as director of the Vanderbilt Vaccine Center, has spent his career hunting for a universal flu vaccine. He has re-engineered how flu vaccines work and is on the edge of creating a single shot that covers all flu strains. In a new initiative announced in October, he will lead an international team of researchers as they launch clinical trials of his new vaccine.(John Russell/Vanderbilt University)

    COVID antibody research conducted at VUMC lands national award

    A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals, and which was optimized and developed by the global pharmaceutical company AstraZeneca, has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine. Now… Read More

    Aug. 25, 2022

  • Dr. James Crowe Jr., professor of medicine, in his lab at Medical Research Building IV. Dr. Crowe is the subject of a feature article in the upcoming Winter 2018 issue of Vanderbilt Magazine. Crowe, who is the Ann Scott Carell Professor of Pediatrics, Pathology, Microbiology and Immunology, as well as director of the Vanderbilt Vaccine Center, has spent his career hunting for a universal flu vaccine. He has re-engineered how flu vaccines work and is on the edge of creating a single shot that covers all flu strains. In a new initiative announced in October, he will lead an international team of researchers as they launch clinical trials of his new vaccine.(John Russell/Vanderbilt University)

    Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization

    On Wednesday, the U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which  protects against COVID-19, discovered last year at Vanderbilt University Medical Center (VUMC). A number of medical conditions result in immune compromise, from treatments for many cancers… Read More

    Dec. 9, 2021